Koreth, John and Schlenk, Richard and Kopecky, Kenneth J and Honda, Sumihisa and Sierra, Jorge and Djulbegovic, Benjamin J and Wadleigh, Martha and DeAngelo, Daniel J and Stone, Richard M and Sakamaki, Hisashi and Appelbaum, Frederick R and Döhner, Hartmut and Antin, Joseph H and Soiffer, Robert J and Cutler, Corey (2009) Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA : the journal of the American Medical Association, 301 (22). pp. 2349-2361. ISSN 1538-3598
Preview |
Text (Complete manuscript)
AppelbaumFJAMAManuscript010711.pdf Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (169kB) | Preview |
Abstract
The optimal treatment of acute myeloid leukemia (AML) in first complete remission (CR1) is uncertain. Current consensus, based on cytogenetic risk, recommends myeloablative allogeneic stem cell transplantation (SCT) for poor-risk but not for good-risk AML. Allogeneic SCT, autologous transplantation, and consolidation chemotherapy are considered of equivalent benefit for intermediate-risk AML.
Item Type: | Article or Abstract |
---|---|
Additional Information: | The final published article is freely available at the URL above. |
DOI: | 10.1001/jama.2009.813 |
PubMed ID: | 19509382 |
NIHMSID: | NIHMS263072 |
PMCID: | PMC3163846 |
Grant Numbers: | CA 18029 |
Keywords or MeSH Headings: | Antineoplastic Agents/therapeutic use; Clinical Trials as Topic; Humans; Leukemia, Myeloid, Acute/mortality/therapy; Remission Induction; Risk Assessment; Stem Cell Transplantation; Survival Analysis; Transplantation, Homologous; |
Subjects: | Diseases > Hematologic and lymphatic diseases > Leukemia Therapeutics > Transplantation > Stem Cell transplantation |
Depositing User: | Library Staff |
Date Deposited: | 07 Jan 2011 20:11 |
Last Modified: | 14 Feb 2012 14:43 |
URI: | http://authors.fhcrc.org/id/eprint/473 |
Repository Administrators Only
View Item |